BCDAW found using ticker (BCDA) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 24 and 9 with a mean TP of 18.33. Given that the stocks previous close was at 4.75 this now indicates there is a potential upside of 285.9%. There is a 50 day moving average of 3.34 and the 200 moving average now moves to 4. The company has a market capitalisation of $32m. Visit the company website at: http://www.biocardia.com
BioCardia, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia is based in San Carlos, California.